Home / Pharma Healthcare / Cancer Immunotherapy - Global Market

Cancer Immunotherapy - Global Market

  • Id : RNR-53847
  • Category : Pharma Healthcare
  • Publish Date : October 2016
  • Pages : 0
  • Format : PDF
License Type

Description
According to Stratistics MRC, the Global Cancer Immunotherapy market is estimated at $54.35 billion in 2015 and is expected to reach $147.25 billion by 2022 growing at a CAGR of 15.3% from 2015 to 2022. Rapid increase in cases of cancer across the globe, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment is hampering the market growth. On the other hand rise in clinical trials against different cancers in immunotherapy is the opportunity for the market growth.

Monoclonal Antibodies accounted for the largest share in product type segment and expected to be fastest growing during forecast period. North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.

Some of the key players in the market include GlaxoSmithKline, Eli Lilly and Company, F. Hoffmann-LA Roche Ltd, Amgen Inc., Ablynx NV, Bristol-Myers Squibb, Janssen Global Services, LLC (Johnson and Johnson), Astrazeneca, Biovest International Inc, Bayer AG, Oxford BioTherapeutics Ltd., Pfizer, Genentech Inc, Merck, Bellicum Pharmaceuticals Inc and Novartis.

Applications Covered:
• Multiple Myeloma
• Prostate Cancer
• Head & Neck Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Other Cancer Types

Product Types Covered:
• Vaccines
o Therapeutic Vaccines
o Prophylactic Vaccines
• Immunomodulators
o Granulocyte/Macrophage Colony-Stimulating Factor  (GM-CSF & G-CSF)
o Oncolytic Virus
§ Immunity as an Ally
§ Immunotherapy
§ Approved Products & Clinical Trails
§ Immunity as an Obstacle
o Interferons (IFN)
o Interleukins (IL)
• Monoclonal Antibodies
o Bispecific Monoclonal Antibodies
o Naked Monoclonal Antibodies
o Conjugated Monoclonal Antibodies
• Cell Therapies
o Dendritic Cells
o Chimeric Antigen Receptor (CAR) T Cell Therapy
• Check Point Inhibitors
o Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
o Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)

End Users Covered:
• Clinics
• Hospital
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain  
o Rest of Europe    
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific    
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements